COVID-19 symptoms: a case-control study, Portugal, March-April 2020

Authors
M. Perez Duque 1,2,3, H. Luccacioni 1,2*, C. Costa 1*, R. Marques 1, D. Antunes 3, L. Hansen 4, R. Sá Machado 1

Affiliations
1 Division of Epidemiology and Statistics, Directorate-General of Health, Lisbon, Portugal
2 European Program for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC)
3 Public Health Unit, ACeS Porto Ocidental, ARS Norte, Porto, Portugal
4 Centre for Infectious Disease Control Netherlands (Clb), RIVM, National Institute for Public Health and Environment, Amsterdam, Netherlands
* Authors contributed equally for the manuscript

Corresponding author: Mariana Perez Duque
Corresponding author email: marianapduque@dgs.min-saude.pt
Summary

COVID-19, although a respiratory illness, has been clinically associated with non-respiratory symptoms. We conducted a negative case-control study to identify the symptoms associated with SARS-CoV-2 positive results in Portugal. Twelve symptoms and signs included in the clinical notification of COVID-19 were selected as predictors, and dependent variable was the RT-PCR test result. Chi-squared tests were used to compare notified cases on sex, age group, health region and presence of comorbidities. The best fit prediction model was selected using a backward stepwise method with an unconditional logistic regression. General and gastrointestinal symptoms were strongly associated with a positive test (p<0.001). In this sense, inclusion of general symptoms such as myalgia, headache and fatigue, as well as diarrhoea, together with actual clinical criteria for suspected cases, already updated and included in COVID-19 case definition, can lead to an increased identification of cases and represent an effective strength for transmission control.

Keywords: coronavirus, symptoms, case-control study

Conflict of interest: None declared.

Author’s contributions

MPD, RSM, HL, CC and RM conceived the study. MPD wrote the manuscript. RSM supervised the overall study. RM was responsible for data acquisition. MPD and CC did data cleaning and MPD analysed the data. RSM, DA and LH critically revised the manuscript.

Acknowledgements

As this is a collaborative work, we would like to say thank you to all public health teams performing case and contact investigation at local and regional levels, the Directorate-General of Health COVID-19 Task-Force members. We acknowledge also Porto Public Health Institute (ISPUP) COVID-19 Task-Force for criticizing study design and data analysis. This study relies on secondary data from National Epidemiological Surveillance System and so, we would like to thank all medical notifiers. As a final point, we also would like to acknowledge Dr. Neil Saad for all inputs regarding overall study concept and data analysis.
COVID-19 symptoms: a case-control study, Portugal – 2020

Introduction

COVID-19, the illness caused by SARS-CoV-2 virus, has a range of flu-like clinical manifestations, including cough, fever, fatigue, myalgia and shortness of breath (1). Although resembling a common cold, this infection can cause serious respiratory illness, such as pneumonia and acute respiratory distress syndrome, especially in high risk individuals (2). Diagnosis of COVID-19 is usually based on detection of SARS-CoV-2 by a reverse transcription polymerase-chain reaction (RT-PCR) testing of oropharyngeal or nasopharyngeal swabs, tracheal aspirate or bronchoalveolar lavage samples (3). Patients with moderate or severe COVID-19 are usually hospitalized for observation and supportive care, since there is currently no specific treatment (4). Early in the pandemic, the presence of non-respiratory symptoms, such as gastrointestinal and smell and taste disorders, were widely reported (5,6). Due to this, attention to COVID-19 patients with non-classic symptoms has been heightened, as well as their predictive value for test positivity (5,7,8).

The Portuguese National Epidemiological Surveillance System (SINAVE) is an electronic epidemiological surveillance system of all nationally notifiable diseases (9). Notification is exclusively and compulsorily online, where clinicians and laboratories report each suspect case in a clinical and laboratorial disease-specific form, respectively (10). The COVID-19 case report form was created in January 2020, and includes a clinical section with symptoms and signs for inquiry, based on international guidelines. The first diagnosed case of COVID-19 in Portugal was on March 1st, a symptomatic male with fever, cough and myalgia, and a recent travel history to a country with an active COVID-19 outbreak (11). This study aims to better understand the clinical presentation of COVID-19 cases at the time of notification in Portugal, in order to update surveillance components. We aimed to identify which symptoms, at the time of notification, were associated with a positive RT-PCR result for SARS-CoV-2 among suspected cases in mainland Portugal between March 1st and April 1st, 2020.

Case definition

For surveillance purposes, the national case definition aligned with guidance from the World Health Organization and the European Centre for Disease Control and Prevention (ECDC) (12,13). Criteria for testing until March 8th were: presence of fever and/or cough and/or shortness of breath, in addition to an epidemiological link with a confirmed case or recent travel history to an affected country (the list of countries was frequently updated by the Portuguese Directorate-General of Health (DGS), according to the COVID-19 risk of transmission). On March 9th, the criteria for SARS-CoV-2 testing was widened to include hospitalized cases with severe pneumonia and no other apparent cause. On March 26th, Portugal
entered the mitigation phase, and the criteria for testing were further expanded to include all cases of acute respiratory distress syndrome with cough or fever (13).

Methods

We extracted retrospective surveillance data on all COVID-19 suspected cases notified to SINAVE until April 1st 2020. Sociodemographic data was collected from each case report form, being automatically feed by the National Patient Record System. Data on clinical symptoms and signs was reported by clinicians on each case report form. An automatized procedure using structured query language algorithm was used to clean and merge both clinical and laboratory SINAVE databases. Posteriorly, a team of clinicians and epidemiologists cleaned, deduplicate, reviewed and cross-checked the data on each suspect case notification. Because completeness of the symptom variables ranged from 33.7 to 46.6%, we selected only those notifications with complete information on symptom variables for analysis. Cases were defined as individuals with a RT-PCR positive test result for SARS-CoV-2 virus and compared to controls, defined as all notifications on individuals with a RT-PCR negative test result for SARS-CoV-2. Controls were chosen as we wanted to better understand the clinical presentation of COVID-19 cases compared to those with similar clinical presentation. No matching methods were used. All suspected cases that met test criteria and were in mainland Portugal during the study period were tested and included in this study, since COVID-19 suspected cases notification in SINAVE is compulsory nationally. All twelve symptoms and signs included in the clinical notification of COVID-19 were selected as predictors (fever as tympanic temperature equal or above 38°C, cough, shortness of breath, headache, myalgia, joint pain, fatigue, sore throat, chest pain, diarrhoea, nausea and abdominal pain). Dependent variable was the RT-PCR test result. Chi-squared tests were used to compare notified cases on sex, age group, health region and presence of comorbidities, defined as binary variable on having a prior diagnosed chronic medical condition. Symptoms were first analysed using unconditional univariate logistic regression, assessed by calculating odds ratios and 95% confidence intervals. For model selection, a backward stepwise method was performed. To correct for possible cofounding, we started with all variables of the study, a multiple adjustment and carried out a multivariate logistic regression. Variables with a p-value <0.001 in univariate analysis were included in the initial model. The best-fit prediction model was selected by choosing the one with the lowest Bayesian Information Criterion (BIC) score. Analyses were performed using STATA v.16 (Statacorp, Texas, United States of America).

Aggregated data was collected in the scope of national epidemiological surveillance, requiring no supplementary ethical clearance. Confidentiality and anonymity were protected, as no individual cases are identifiable in this analysis.
COVID-19 suspected cases

From 51 726 COVID-19 suspected cases notifications, 11 442 had sufficiently complete symptom data for analysis: 2 031 (15.96%) tested positive for SARS-CoV-2. Among all COVID-19 suspected cases, 56.98% were female (Table 1), although this proportion was slightly lower among cases (52.1%, p<0.001). Median age of controls was 43 years (SD±22.6), while among cases was 50 years (SD±19.8). The North region was the most affected area, with circa 50% of test-positive cases. A larger proportion of individuals in the SARS-CoV-2 test-positive group had comorbid conditions (p<0.001).

Cases and controls differed significantly on age group, sex, health region and presence of comorbidities. Because cases and controls were not matched, we included these variables in further analysis of symptoms for multiple adjustment.

COVID-19 symptoms

Among test-positive cases, cough (73.0%, n = 1 483), fever (59.7%, n = 1 212), myalgia (43.9%, n = 891), headache (40.0%, n = 812) and fatigue (38%, n= 771) were most frequently reported (Table 2).

At the time of notification, presence of general symptoms such as fever, myalgia, arthralgia, headache and fatigue, as well as gastrointestinal symptoms (diarrhoea and nausea or vomiting) were positively associated with COVID-19. Symptoms of chest pain, shortness of breath, and abdominal pain, were not associated with a positive test result in the univariate analysis.

For symptoms included in the case definition (presence of fever or cough or shortness of breath), only cases presenting with fever (alone or in combination with other symptoms), were strongly associated with a positive test for SARS-CoV-2 (crude odds ratio (OR) 2.29, 95% CI 2.08-2.53). Those presenting with cough, alone or in combination with other symptoms, were 20% less likely to test positive for SARS-CoV-2 virus (95% CI 0.72-0.89) and for those presenting only with shortness of breath, the association with positive test outcome was not statistically significant (crude OR 0.94, 95% CI 0.84-1.05).

After multiple adjustment for symptoms, as well as age group, sex and health region, the best-fit model did not retain nausea or vomiting, arthralgia and presence of comorbidities (Table 3). In this multivariate model, presence of fever, myalgia, headache, fatigue or diarrhoea were all strongly associated with the outcome of positive SARS-CoV-2 test result.
General symptoms on this model were strongly associated with a positive test. Those who had fever were almost twice as likely to have a positive test as those presenting without fever (adjusted OR 1.96, 95% CI 1.76-2.17). For respiratory symptoms, the presence of cough or sore throat was negatively associated with COVID-19 test positivity (p<0.001). Diarrhoea increased by 42% the odds of testing positive (aOR 1.42 95% CI 1.22-1.65). Running the same model only with multiple adjustment for symptoms, without including age, sex, health region and presence of comorbidities (possible cofounders) led to the same conclusions within groups of symptoms (Supplementary table S1).

Discussion

Based on the results presented, symptoms most prevalent in SARS-CoV-2 positive cases were cough and fever, demonstrating testing criteria previously described in case definition. Nevertheless, we acknowledge also that myalgia, fatigue and headache, as classified as general symptoms, were presented each in more than one third of COVID-19 cases. Indeed, ECDC last updated case definition criteria on May 29th 2020, acknowledging additional less specific symptoms to be considered in clinical criteria. Headache, chills, myalgia, fatigue, vomiting and/or diarrhoea were described as to be considered (14).

In our study, non-respiratory symptoms, including general and gastrointestinal symptoms (diarrhoea) were strongly associated with a positive test for SARS-CoV-2. Based on twelve symptoms analysed, the most parsimonious model retained nine symptoms with the strongest association. Presence of fever, myalgia, headache, fatigue or diarrhoea was associated with a COVID-19 laboratory confirmation. Compared with other respiratory viruses, fatigue, headache and myalgia were more common among human coronavirus infected patients (15). This study highlights the predictive value of general non-respiratory symptoms as a differential tool to distinguish COVID-19 cases in the universe of respiratory symptoms patients.

This is not the first study where respiratory symptoms in COVID-19 cases played a minor role in predicting laboratory test results for SARS-CoV-2 (5,8). Although respiratory symptoms, such as cough, are frequent among COVID-19 cases and other human coronavirus infections, in our study COVID-19 cases report less cough comparing to other respiratory viruses and less shortness of breath than other human coronavirus (15). Furthermore, some symptoms initially not diagnosed or not associated with this virus are being reported, such as smell and taste disorders (6). In consequence, the addition of general and gastrointestinal symptoms proven to be strongly associated with a positive test for SARS-CoV-2, can be an asset on cases identification and resource saving. In fact, this study contributes in evidence that supports last updates on COVID-19 case definitions, highlighting reported less specific symptoms (14).
This study has some limitations, as it reflects clinical presentation of suspected and confirmed cases of COVID-19 at the time of notification. This means that we were assessing early symptoms in some cases, and several days of symptoms in others. Although methods exist to deal with missing data, completeness of data was a major issue in this analysis: due to poor completeness, we opted to analyse complete case reports to improve confidence in our results, though, we cannot exclude the presence of a selection bias. In this sense we compared our sample with all COVID-19 suspected cases regarding age, sex, presence of comorbidities and health region. Our sample was younger, had higher female proportion and reported less comorbidities at the time of notification ($p<0.001$) (further details in Supplementary material S2).

Although there is evidence on sex differences regarding COVID-19 mortality, it is still not clear that the effect of sex on disease presentation and diagnosis. (16,17). There is also evidence on older age groups having a higher risk of atypical disease presentation (asthenia, delirium, fall), that is likely related to the higher prevalence of comorbidities, being one the variables that we adjusted for in our analysis (18). Furthermore, due to the younger mean age in this sample, it is expected that the occurrence of SARS-CoV-2 positive test is higher in this group due to higher probability of typical clinical presentation, possibly overestimating the reported magnitude of the association. Individuals in our sample had a lower prevalence of comorbidities, leading to a likely underestimation of the association between having a prior medical precondition and a positive test result, since having the first increases the risk for SARS-CoV-2 infection (19). In this comparison, variables presented small statistically significant differences, in both directions, and not surprisingly due to correspondent population and sample sizes. Due to study design, identification of symptoms was dependent on accurate clinical documentation on SINAve predefined questionnaire. Moreover, we acknowledge that some symptom misclassification likely exists, but expect that it is non-differential, as test outcomes were unknown at the time of their documentation.

Our results can be compared with settings using the same case definition and similar surveillance system, due to comprehensiveness of detection and reporting of patients.

**Conclusion**

These results highlight that general and gastrointestinal symptoms, at the time of notification, are strongly associated with a positive test for SARS-CoV-2. In contrast, the presence of respiratory symptoms was less likely to lead to a positive test for SARS-CoV-2. Based on our findings, respiratory symptoms, such as cough, although frequent among cases, are negatively associated with COVID-19 case status. In this sense, inclusion of general symptoms such as myalgia, headache and fatigue, as well as diarrhoea, together with actual clinical criteria for suspected cases, already
updated and included in COVID-19 case definition, can lead to an increased identification of cases and represent an effective strength for transmission control.

Disclosures
The contents of this article are solely the responsibility of the authors and do not necessarily represent the views of the affiliated institutions. We declare that we received no funding.

Data Availability Statement
The data that support the findings of this study are available from the Portuguese Directorate General of Health (DGS). Restrictions apply to the availability of these data, which were used under licence for this study. Data are available from the authors with the permission of DGS.

References
1. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of Autoimmunity [Internet]. 2020;109:102433. Available from: http://www.sciencedirect.com/science/article/pii/S0896841120300469
2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England) [Internet]. 2020/01/24. 2020 Feb 15;395(10223):497–506. Available from: https://pubmed.ncbi.nlm.nih.gov/31986264
3. Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, et al. COVID-19 diagnosis and management: a comprehensive review. Journal of Internal Medicine [Internet]. n/a(n/a). Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/joim.13091
4. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA - Journal of the American Medical Association. 2020;323(18).
5. Nobel YR, Phipps M, Zucker J, Lebwohl B, Wang TC, Sobieszczyk ME, et al. Gastrointestinal Symptoms and COVID-19: Case-Control Study from the United States. Gastroenterology. 2020 Apr;
6. Beltrán-Corbella A, Chico-García JL, Martínez-Poles J, Rodríguez-Jorge F, Natera-Villalba E, Gómez-Corral J, et al. Acute-onset smell and taste disorders in the context of COVID-19: a pilot multicentre polymerase chain reaction based case-control study. European Journal of Neurology [Internet]. n/a(n/a). Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/ene.14273
7. Jin X, Lian JS, Hu JH, Gao J, Zheng L, Zhang YM, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020;1–8.
8. Tostmann A, Bradley J, Bousema T, Yiek W-K, Holwerda M, Bleeker-Rovers C, et al. Strong associations and moderate predictive value of early symptoms for SARS-CoV-2 test positivity among healthcare workers, the Netherlands, March 2020. Eurosurveillance. 2020;25(16).
9. Assembleia da República. Lei n.º 81/2009 de 21 de Agosto. Diário da República 2009 p. 5491–5.
10. Ministério da Saúde. Portaria n.° 248/2013 de 5 de agosto. Diário da República. 2013;1.ª série(N.º 149):4624–7.

11. Portuguese Directorate-General of Health. Relatório de Situação n°001, 3 de março 2020 [Internet]. 2020. Available from: https://covid19.min-saude.pt/wp-content/uploads/2020/03/Relatorio-de-Situacao-1.pdf

12. European Centre for Disease Prevention and Control. Case definition and European surveillance for COVID-19, as of 2 March 2020 [Internet]. 2020. Available from: https://www.ecdc.europa.eu/en/case-definition-and-european-surveillance-human-infection-novel-coronavirus-2019-ncov

13. Portuguese Directorate-General of Health. Norma - Abordagem do Doente com Suspeita ou Infeção por SARS-CoV-2. Available from: https://www.dgs.pt/directrizes-da-dgs/normas-e-circulares-normativas/norma-n-0042020-de-23032020-pdf.aspx

14. European Centre for Disease Prevention and Control. Case definition for coronavirus disease 2019 (COVID-19), as of 29 May 2020. 2020.

15. Friedman N, Alter H, Hindiyeh M, Mendelson E, Shemer Avni Y, Mandelboim M. Human Coronavirus Infections in Israel: Epidemiology, Clinical Symptoms and Summer Seasonality of HCoV-HKU1. Viruses. 2018 Sep;10(10).

16. Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. Biology of Sex Differences [Internet]. 2020;11(1):29. Available from: https://doi.org/10.1186/s13293-020-00304-9

17. Palaiodimos L, Kokkinidis DG, Li W, Karamanis D, Ognibene J, Arora S, et al. Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. Metabolism. 2020 Jul;108:154262.

18. Godaert L, Proye E, Demoustier-Tampere D, Coulibaly PS, Hequet F, Dramé M. Clinical characteristics of older patients: The experience of a geriatric short-stay unit dedicated to patients with COVID-19 in France. Vol. 81, The Journal of infection. 2020. p. e93–4.

19. Jain V, Yuan J-M. Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis. International Journal of Public Health. 2020 Jun;65(5):533–46.
Table 1. Description of COVID-19 notifications with complete data, as of date of notification, by SARS-CoV-2 test result, Portugal, March-April 2020 (n= 11 442)

|                          | Total n= 11 442 | SARS-CoV-2 positive n= 2 031 | SARS-CoV-2 negative n= 9 411 | p value (Chi-squared test) |
|--------------------------|-----------------|------------------------------|-------------------------------|---------------------------|
|                          | n               | %                           | n                             | %                        |
|                           | n= 11 442       | SARS-CoV-2 positive n= 2 031 | SARS-CoV-2 negative n= 9 411 | p value (Chi-squared test) |
| Sex                      |                 |                             |                               |                          |
| Male                     | 4 922           | 43.0                        | 973                           | 47.0                      | 3 949                       | 42.0                        | <0.001                      |
| Female                   | 6 520           | 57.0                        | 1 058                         | 52.1                      | 5 462                       | 58.0                        |                                    |
| Age group                |                 |                             |                               |                          |
| 0-9y                     | 869             | 7.6                         | 35                            | 1.7                       | 834                         | 8.9                         |                                    |
| 10-19y                   | 625             | 5.5                         | 75                            | 3.7                       | 550                         | 5.8                         |                                    |
| 20-29y                   | 1 275           | 11.1                        | 204                           | 10.0                      | 1 071                       | 11.4                        |                                    |
| 30-39y                   | 1 939           | 17.0                        | 336                           | 16.5                      | 1 603                       | 17.0                        |                                    |
| 40-49y                   | 2 073           | 18.1                        | 348                           | 17.1                      | 1 725                       | 18.3                        | <0.001                      |
| 50-59y                   | 1 776           | 15.5                        | 391                           | 19.3                      | 1 385                       | 14.7                        |                                    |
| 60-69y                   | 1 219           | 10.7                        | 288                           | 14.2                      | 931                         | 9.9                         |                                    |
| 70-79y                   | 791             | 6.9                         | 185                           | 9.1                       | 606                         | 6.4                         |                                    |
| 80y+                     | 875             | 7.7                         | 169                           | 8.3                       | 706                         | 7.5                         |                                    |
| Health region            |                 |                             |                               |                          |
| North                    | 5 007           | 43.8                        | 1 033                         | 50.9                      | 3 974                       | 42.2                        |                                    |
| Center                   | 1 636           | 14.3                        | 261                           | 12.9                      | 1 375                       | 14.6                        |                                    |
| Lisbon and Tagus Valley  | 3 262           | 28.5                        | 563                           | 27.7                      | 2 699                       | 28.7                        |                                    |
| Alentejo                 | 398             | 3.5                         | 28                            | 1.4                       | 370                         | 3.9                         | <0.001                      |
| Algarve                  | 944             | 8.3                         | 96                            | 4.7                       | 848                         | 9.0                         |                                    |
| Madeira                  | 115             | 1.0                         | 25                            | 1.2                       | 55                          | 0.6                         |                                    |
| Azores                   | 80              | 0.7                         | 25                            | 1.2                       | 90                          | 1.0                         |                                    |

Comorbidities

Downloaded from https://www.cambridge.org/core, IP address: 207.241.225.241, on 23 Feb 2021 at 21:59:04, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/S095026882100042X
|    | No  | 7 030 | 61.4 | 1 141 | 56.2 | 5 889 | 62.6 | <0.001 |
|----|-----|-------|------|-------|------|-------|------|--------|
| Yes| 4 412 | 38.6  | 890  | 43.8  | 3 522 | 37.4  |      |        |
Table 2. Frequency and univariate association of COVID-19 symptoms with test outcome, among SINAVE notified cases, Portugal, March-April 2020 (n= 11 442)

| Symptoms      | Total (n= 11 442) | SARS-CoV-2 positive (n= 2 031) | SARS-CoV-2 negative (n= 9 411) | OR (95% CI) | p value | aOR (95% CI) | p value |
|---------------|-------------------|-------------------------------|-------------------------------|-------------|---------|-------------|---------|
|               | n     | %        | n     | %        | n     | %        |         |           |         |         |
| General       |       |          |       |          |       |          |         |           |         |         |
| Fever         | 4 902 | 42.8     | 1 212 | 59.7     | 3 690 | 39.2     | 2.29    | 2.08-2.53 | <0.001  | 2.36    | 2.14-2.61 | <0.001  |
| Myalgia       | 3 399 | 29.7     | 891   | 43.9     | 2 508 | 26.7     | 2.15    | 1.95-2.37 | <0.001  | 2.19    | 1.98-2.42 | <0.001  |
| Arthralgia    | 449   | 3.9      | 124   | 6.1      | 325   | 3.5      | 1.82    | 1.47-2.25 | <0.001  | 1.85    | 1.49-2.30 | <0.001  |
| Headache      | 3 545 | 31.0     | 812   | 40.0     | 2 733 | 29.0     | 1.62    | 1.47-1.80 | <0.001  | 1.83    | 1.65-2.03 | <0.001  |
| Fatigue       | 3 105 | 27.1     | 771   | 38.0     | 2 334 | 24.8     | 1.50    | 1.39-1.61 | <0.001  | 1.75    | 1.58-1.94 | <0.001  |
| Chest pain    | 1 598 | 14.0     | 262   | 12.9     | 1 336 | 14.2     | 0.90    | 0.78-1.03 | 0.127   | 0.90    | 0.78-1.04 | 0.169   |
| Respiratory   |       |          |       |          |       |          |         |           |         |         |          |         |
| Shortness of breath | 2 834 | 24.8 | 483 | 23.8 | 2 351 | 25.0 | 0.94 (0.84-1.05) | 0.256 | 0.79 (0.70-0.89) | <0.001 |
| Cough         | 8 738 | 76.4     | 1 453 | 73.0     | 7 255 | 77.1     | 0.80    | 0.72-0.89 | <0.001  | 0.82    | 0.73-0.92 | <0.001  |
| Sore throat   | 3 322 | 29.0     | 500   | 24.6     | 2 822 | 30.0     | 0.76    | 0.68-0.85 | <0.001  | 0.85    | 0.76-0.95 | 0.004   |
| Gastrointestinal |       |          |       |          |       |          |         |           |         |         |          |         |
| Diarrhoea     | 1 144 | 10.0     | 290   | 14.3     | 854   | 9.1      | 1.70    | 1.45-1.93 | <0.001  | 1.76    | 1.53-2.04 | <0.001  |

This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.
| Symptoms         | Count | Mean | SD  | Median | OR (95% CI) | p-value | Crude OR (95% CI) | p-value |
|------------------|-------|------|-----|--------|-------------|---------|-------------------|---------|
| Nausea or vomiting | 907   | 7.9  | 202 | 10.0   | 705         | 7.5     | **1.36 (1.16-1.61)** | <0.001 |
|                  |       |      |     |        |             |         | **1.43 (1.21-1.69)** | <0.001 |
| Abdominal pain   | 670   | 5.9  | 134 | 6.6    | 536         | 5.7     | 1.17 (0.96-1.42)  | 0.117  |
|                  |       |      |     |        |             |         | **1.22 (1.00-1.48)** | 0.054  |

* Symptoms, age group, sex, health region and comorbidities adjusted
Table 3. Multivariate model on COVID-19 symptoms among SINAVE notified cases, Portugal, March-April 2020 (n= 11 442)

| Symptoms          | aOR^1 (95% CI) | p value |
|-------------------|---------------|---------|
| **General**        |               |         |
| Fever             | 1.96 (1.78-2.18) | <0.001 |
| Myalgia           | 1.64 (1.46-1.84) | <0.001 |
| Headache          | 1.44 (1.29-1.62) | <0.001 |
| Fatigue           | 1.24 (1.11-1.39) | <0.001 |
| **Respiratory**   |               |         |
| Cough             | 0.75 (0.67-0.85) | <0.001 |
| Sore throat       | 0.71 (0.63-0.80) | <0.001 |
| **Gastrointestinal** |          |         |
| Diarrhoea         | 1.42 (1.22-1.65) | <0.001 |

^1 Symptoms, age group, sex and health region adjusted